19:04 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Colitis Mouse studies suggest inhibiting IL-17F could help treat colitis. In a mouse model of chemical-induced colitis, systemic knockout of IL-17F decreased colitis severity compared with normal IL-17F expression, and a mAb against IL-17F decreased...
21:18 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermatitis Mouse studies identified nine S. aureus and host factors as targets for treatment of dermatitis associated with S. aureus infections. In primary mouse and human keratinocytes treated with supernatants from S. aureus cultures, knockout...
19:52 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

UCB's bimekizumab meets in Phase IIb for ankylosing spondylitis

UCB S.A. (Euronext:UCB) reported data from the Phase IIb BE AGILE trial in 303 patients with active ankylosing spondylitis showing that subcutaneous bimekizumab (UCB4940) every four weeks met the primary endpoint of a greater proportion...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
21:04 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

UCB's bimekizumab meets in Phase IIb for psoriasis

UCB S.A. (Euronext:UCB) reported top-line data from the Phase IIb BE ABLE trial in 250 patients with moderate to severe chronic plaque psoriasis showing that subcutaneous bimekizumab (UCB4940) every 4 weeks met the primary endpoint...
21:17 , Jul 21, 2017 |  BC Extra  |  Clinical News

UCB psoriasis candidate headed for Phase III

UCB S.A. (Euronext:UCB) said bimekizumab (UCB4940) led to 90% clearance of plaque psoriasis per the Psoriasis Area and Severity Index (PASI 90) in up to 79% of patients in the Phase IIb BE ABLE study,...
04:22 , Apr 7, 2017 |  BC Week In Review  |  Company News

Avillion, Merck KGaA deal

The companies partnered to develop Merck’s M1095 (ALX-0761) to treat plaque psoriasis. Avillion will be responsible for developing the candidate through Phase III testing and will also finance development through to a regulatory submission. Phase...
02:11 , Feb 23, 2017 |  BC Week In Review  |  Clinical News

M1095: Ph Ib data

A double-blind, German Phase Ib trial in 41 patients with moderate to severe psoriasis showed that 30, 60, 120 and 240 mg doses of subcutaneous M1095 on days 1, 15 and 29 led to PASI...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

Bimekizumab: Phase Ib data

Top-line data from a double-blind, European Phase Ib trial in 52 patients with psoriatic arthritis who had inadequate responses to >=1 DMARD and/or 1 biologic showed that pooled data from the top 3 doses (n=30)...
02:37 , Feb 28, 2015 |  BC Extra  |  Company News

Ablynx: Merck Serono may unwind deal

Ablynx N.V. (Euronext:ABLX) said during its 4Q14 earnings call that partner Merck Serono S.A. is likely to terminate a 2013 deal to develop Nanobodies against cancer, immunology and neurology targets. Ablynx did not respond to...